|Bid||1.59 x 21500|
|Ask||1.60 x 2900|
|Day's Range||1.55 - 1.70|
|52 Week Range||0.96 - 2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.86|
Shares of Novavax Inc. soared 12% in premarket trade Friday, after J.P. Morgan analyst Eric Joseph swung to bullish from bearish, citing a favorable risk-reward investment profile ahead of pivotal trial data on its RSV treatment for infants, due out in the first quarter of 2019. Joseph raised his rating two notches to overweight from underweight. He said the shares have already pulled back sharply from recent highs on "receding expectations" regarding the trial outcome. As a result, he sees 50% to over 100% potential upside in the stock after the results, and about an 80% downside risk on a trial failure, but that is viewed as a "less likely" event. "Looking beyond the phase 3 readout, we believe positive PREPARE data would support broader development to additional at-risk populations and their inclusion in the model (pediatric patients under 2yo)," Joseph wrote in a note to clients. The stock had tumbled 39% from the Feb. 20 17-month closing high of $2.42. Over the same time, the iShares Nasdaq Biotechnology ETF has climbed 9.2% and the S&P 500 has advanced 7.9%.
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS ...
GAITHERSBURG, Md., Aug. 28, 2018-- Novavax, Inc. today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13 th Annual Biotech Conference in September.. ...
Novavax (NVAX) generated revenue of $10.77 million in the second quarter compared to $6.73 million in the comparable period in 2017. The increase in the company’s revenue resulted from a $2 million increase in the Bill and Melinda Gates Foundation grant revenue due to higher enrolment in Novavax’s Prepare trial and an additional $2 million from increased activities from Novavax AB. The general and administrative expenses incurred by Novavax decreased from $8.94 million in the second quarter of 2017 to $8.22 million in the second quarter of 2018.
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Novavax Delivers on Key Milestones Supporting its 2018 Objectives. Company to Host Conference Call Today at 4:30 pm ET. GAITHERSBURG, Md., Aug. 08, 2018-- Novavax, Inc. today announced its financial results ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novavax, Inc. (NASDAQ: NVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
GAITHERSBURG, Md., Aug. 01, 2018-- Novavax, Inc. today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August ...
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.